#Osimertinib #IndonesiaPharma #API #PharmaSourcing #Oncology #Pharmaceuticals #CDMO #PharmaIndonesia #APIImport #PharmaSupplyChain
@nikolospharma.bsky.social
@nikolospharma.bsky.social@nikolospharma.bsky.social
@dominic-tyer.bsky.socialLooking beyond short-term turmoil, Syngene has revamped its leadership and is building capacity as it eyes growth and emerging modalities
@nikolospharma.bsky.social
@nikolospharma.bsky.social
@newsen.bsky.socialCordenPharma Expands Aseptic Filling Capacity to 500 Million Injectable Units Annually #Italy #CDMO #CordenPharma #sterile_injectables #Caponago
@newsen.bsky.socialCordenPharma Expands Aseptic Filling Capacity to 500 Million Sterile Injectable Units Annually #Switzerland #CDMO #CordenPharma #Caponago #EUA
@newsen.bsky.socialCordenPharma Expands Aseptic Filling Capacity to 500 Million Sterile Injectable Units Annually #Switzerland #CDMO #CordenPharma #sterile_injectables #Caponago
@newsramp.comScinai Immunotherapeutics (NASDAQ: SCNI) refocuses R&D on its NanoAb platform with two IL-17 programs and targets ~$5M in CDMO revenue for 2026 after terminating PC111 licensing arrangements. #Biotech #CDMO
@newsen.bsky.socialPharmaceutical CDMO Market Expected to Grow to US$ 270.3 Billion by 2031 Driven by Biologic Demand #None #pharmaceutical #CDMO #Biologics
@newsen.bsky.socialScinai Immunotherapeutics Shifts Focus to NanoAb and CDMO Growth Strategies #Scinai_Immunotherapeutics #Israel #Jerusalem #CDMO #NanoAb_Platform